biosimilars

Four oncology treatment advances to watch
Four oncology treatment advances to watchExperts say a cancer care revolution is here. Here’s a closer look at some advancements in cancer treatments to watch.
Biosimilars can save billions of healthcare dollarsAnalysis from RAND helps frame the potential of biosimilars to reduce spending on biologics.
Report: Medicare Biosimilar Changes Could Save BillionsA change in reimbursement policy for biosimilar drugs could save CMS billions.
FDA okays biosimilar for several cancers
FDA okays biosimilar for several cancersWhile FDA has approved a handful of biosimilar drugs, the agency just approved the first biosimilar that treats a variety of types of cancer.
Will new biosimilars hurt blockbuster autoimmune drug?
Will new biosimilars hurt blockbuster autoimmune drug?New biosimilars may harm the sales of this autoimmune blockbuster.
Biosimilars Market Taking Off in the United StatesAfter many years of speculation, a number of biosimilar drugs are hitting the U.S. market.
Pharmacists: Key Players as Biosimilars Enter the MarketPharmacists will have a central role in educating about biosimilar drugs.
Biosimilars Come  to Community Pharmacy
Biosimilars Come to Community PharmacyBiosimilars are now being dispensed from community pharmacies.
Brace for a barrage of biosimilarsThe next few years will see the healthcare industry bracing itself for new biosimilar products for a range of illnesses from oncology to rheumatoid arthritis.
Top 3 factors in biosimilar coverageAn Avalere study has interesting findings about payer acceptance of biosimilars.